Cardio-Cerebrovascular Protective Effects of Valsartan in High-Risk Hypertensive Patients With Coronary Artery Disease (from the Kyoto Heart Study)

被引:14
|
作者
Shiraishi, Jun [1 ]
Sawada, Takahisa [2 ]
Koide, Masahiro [2 ]
Yamada, Hiroyuki [2 ]
Matsubara, Hiroaki [2 ]
机构
[1] Kyoto First Red Cross Hosp, Dept Cardiol, Kyoto, Japan
[2] Kyoto Prefectural Univ, Sch Med, Dept Cardiovasc Med, Kyoto 606, Japan
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2012年 / 109卷 / 09期
关键词
CASE-J TRIAL; CARDIOVASCULAR EVENTS; SUBANALYSIS; MORBIDITY; MORTALITY; RAMIPRIL;
D O I
10.1016/j.amjcard.2011.12.025
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The objective was to examine whether previous coronary artery disease (CAD) influences the add-on effects of the angiotensin II receptor blocker (ARB) valsartan on cardio-cerebrovascular morbidity and mortality in high-risk hypertensive patients who participated in the Kyoto Heart Study. The primary end point was the same as in the main study: a composite of new-onset and/or worsening of cardiovascular and cerebrovascular events. Median follow-up was 3.27 years. According to the presence of previous CAD at baseline, the study population was divided into 2 groups (with CAD, n = 707; without CAD, n = 2,324) in which primary end-point events occurred more frequently in patients with CAD than in patients without CAD (15.1% vs 5.6%, hazard ratio [HR] 2.68, 95% confidence interval [CI] 2.11 to 3.42). Add-on valsartan significantly decreased the occurrence of the primary end-point events in patients with CAD (11.3% vs 19.0%, HR 0.59, 95% CI 0.41 to 0.85) and without CAD (3.7% vs 7.6%, HR 0.49, 95% CI 0.34 to 0.70) compared to non-ARB treatment. In the presence of previous CAD, patients with valsartan add-on treatment had a significantly lower prevalence of angina pectoris and stroke than those with non-ARB treatment, whereas the valsartan add-on effects on angina and stroke were not significant in the absence of CAD. Changes in blood pressure during the follow-up period did not differ significantly between study subgroups. In conclusion, in the presence or absence of previous CAD, valsartan add-on treatment prevented more cardio-cerebrovascular events than conventional non-ARB treatment in high-risk hypertensive patients. In addition, valsartan add-on treatment conferred not only an antianginal effect but also stroke prevention exclusively in hypertensive patients with CAD compared to those without CAD. (C) 2012 Elsevier Inc. All rights reserved. (Am J Cardiol 2012;109:1308-1314)
引用
收藏
页码:1308 / 1314
页数:7
相关论文
共 50 条
  • [21] Biomarkers for identification of high-risk coronary artery plaques in patients with suspected coronary artery disease
    Pedersen, Gitte
    Dahl, Jonathan Nortoft
    Rasmussen, Laust Dupont
    Blavnsfeldt, Anne-Birgitte Garm
    Bottcher, Sidsel Hauge
    Bottcher, Matias Hauge
    Nyegaard, Mette
    Nissen, Louise
    Winther, Simon
    JOURNAL OF CARDIOVASCULAR COMPUTED TOMOGRAPHY, 2024, 18 (05) : 467 - 475
  • [22] Rationale and design of the KYOTO HEART study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events (vol 23, pg 188, 2009)
    Sawada, T.
    Takahashi, T.
    Yamada, H.
    Dahloef, B.
    Matsubara, H.
    JOURNAL OF HUMAN HYPERTENSION, 2013, 27 (09) : 580 - 580
  • [23] Management of High-Risk Patients With Aortic Stenosis and Coronary Artery Disease
    Wendt, Daniel
    Kahlert, Philipp
    Lenze, Tim
    Neuhaeuser, Markus
    Price, Vivien
    Konorza, Thomas
    Erbel, Raimund
    Jakob, Heinz
    Thielmann, Matthias
    ANNALS OF THORACIC SURGERY, 2013, 95 (02): : 599 - 605
  • [24] Clinical Significance of Microalbuminuria in High-Risk Patients With Coronary Artery Disease
    Kojima, Sunao
    Ogawa, Hisao
    CIRCULATION JOURNAL, 2011, 75 (12) : 2765 - 2766
  • [25] Secondary prevention of coronary artery disease in high-risk diabetic patients
    Giorda, C
    Maggini, M
    Alegiani, SS
    Turco, S
    Raschetti, R
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2003, 13 (04) : 238 - 243
  • [26] A Clinical Model to Identify Patients With High-Risk Coronary Artery Disease
    Yang, Yelin
    Chen, Li
    Yam, Yeung
    Achenbach, Stephan
    Al-Mallah, Mouaz
    Berman, Daniel S.
    Budoff, Matthew J.
    Cademartiri, Filippo
    Callister, Tracy Q.
    Chang, Hyuk-Jae
    Cheng, Victor Y.
    Chinnaiyan, Kavitha
    Cury, Ricardo
    Delago, Augustin
    Dunning, Allison
    Feuchtner, Gudrun
    Hadamitzky, Martin
    Hausleiter, Joerg
    Karlsberg, Ronald P.
    Kaufmann, Philipp A.
    Kim, Yong-Jin
    Leipsic, Jonathon
    LaBounty, Troy
    Lin, Fay
    Maffei, Erica
    Raff, Gilbert L.
    Shaw, Leslee J.
    Villines, Todd C.
    Min, James K.
    Chow, Benjamin J. W.
    JACC-CARDIOVASCULAR IMAGING, 2015, 8 (04) : 427 - 434
  • [27] Aortic Valve Sclerosis in High-Risk Coronary Artery Disease Patients
    Myasoedova, Veronika A.
    Genovese, Stefano
    Cavallotti, Laura
    Bonomi, Alice
    Chiesa, Mattia
    Campodonico, Jeness
    Rondinelli, Maurizio
    Cosentino, Nicola
    Baldassarre, Damiano
    Veglia, Fabrizio
    Pepi, Mauro
    Alamanni, Francesco
    Colombo, Gualtiero, I
    Marenzi, Giancarlo
    Poggio, Paolo
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [28] EFFECTIVENESS OF CORONARY HEART-DISEASE RISK MANAGEMENT IN HIGH-RISK PATIENTS
    LEITHA, T
    STAUDENHERZ, A
    BACHMANN, B
    DUDCZAK, R
    CLINICAL CARDIOLOGY, 1994, 17 (03) : 123 - 130
  • [29] The usefulness of coronary artery calcium scoring and computed tomography angiography to detect patients at high-risk for coronary heart disease
    Lembcke, Alexander
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009, 10 (09) : 947 - 954
  • [30] Red Meat Consumption and Risk of Cardio-Cerebrovascular Disease in Chinese Older Adults Evidence from the China Kadoorie Biobank Study
    Sun, Xiaojia
    Sun, Ruihong
    Zhang, Liming
    INTERNATIONAL HEART JOURNAL, 2023, 64 (04) : 654 - 662